(CNXC) Concentrix - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US20602D1019
Stock: CX Solutions, Digital Transformation, Analytics, BPO Services, AI Technology
Total Rating 25
Risk 65
Buy Signal 0.05
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.94% |
| Yield on Cost 5y | 1.35% |
| Yield CAGR 5y | 52.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 12.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 60.7% |
| Relative Tail Risk | -12.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.00 |
| Alpha | -31.56 |
| Character TTM | |
|---|---|
| Beta | 1.026 |
| Beta Downside | 1.364 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.62% |
| CAGR/Max DD | -0.44 |
Description: CNXC Concentrix January 11, 2026
Concentrix Corporation (NASDAQ: CNXC) delivers end-to-end customer-experience (CX) services, ranging from process optimization and AI-driven automation to analytics and digital transformation, across a broad set of verticals such as technology, retail, travel, communications, financial services, and healthcare. Its portfolio includes front- and back-office BPO, self-service GenAI assistants, voice-of-customer analytics, and industry-specific CX design engineering.
Key operational metrics (FY 2023) show revenue of roughly $4.2 billion, a year-over-year increase of about 5 %, and an operating margin near 6 %, reflecting modest pricing power amid rising demand for AI-augmented BPO solutions. The outsourced-services sector is projected to expand at a 6 % CAGR through 2028, driven by corporate cost-containment, nearshoring trends, and accelerated digital-transformation spending-factors that directly support Concentrix’s growth outlook. (Assumption: FY 2023 figures are based on the latest public filings; actual Q4 results may adjust these numbers.)
For a deeper dive into CNXC’s valuation metrics and peer comparison, you might explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: -1.28b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.74 > 1.0 |
| NWC/Revenue: 9.04% < 20% (prev 8.80%; Δ 0.24% < -1%) |
| CFO/TA 0.07 > 3% & CFO 807.0m > Net Income -1.28b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.1m) vs 12m ago -4.61% < -2% |
| Gross Margin: 33.30% > 18% (prev 0.36%; Δ 3294 % > 0.5%) |
| Asset Turnover: 86.37% > 50% (prev 80.21%; Δ 6.16% > 0%) |
| Interest Coverage Ratio: -3.07 > 6 (EBITDA TTM -728.7m / Interest Expense TTM 290.3m) |
Altman Z'' -0.10
| A: 0.08 (Total Current Assets 3.08b - Total Current Liabilities 2.20b) / Total Assets 10.76b |
| B: -0.02 (Retained Earnings -177.0m / Total Assets 10.76b) |
| C: -0.08 (EBIT TTM -891.9m / Avg Total Assets 11.38b) |
| D: -0.05 (Book Value of Equity -429.5m / Total Liabilities 8.02b) |
| Altman-Z'' Score: -0.10 = B |
Beneish M -3.18
| DSRI: 1.02 (Receivables 2.00b/1.93b, Revenue 9.83b/9.62b) |
| GMI: 1.08 (GM 33.30% / 35.86%) |
| AQI: 0.92 (AQ_t 0.65 / AQ_t-1 0.70) |
| SGI: 1.02 (Revenue 9.83b / 9.62b) |
| TATA: -0.19 (NI -1.28b - CFO 807.0m) / TA 10.76b) |
| Beneish M-Score: -3.18 (Cap -4..+1) = AA |
What is the price of CNXC shares?
As of February 08, 2026, the stock is trading at USD 39.93 with a total of 1,064,230 shares traded.
Over the past week, the price has changed by +6.91%, over one month by -8.15%, over three months by +10.03% and over the past year by -14.49%.
Over the past week, the price has changed by +6.91%, over one month by -8.15%, over three months by +10.03% and over the past year by -14.49%.
Is CNXC a buy, sell or hold?
Concentrix has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy CNXC.
- StrongBuy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CNXC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 62.2 | 55.8% |
| Analysts Target Price | 62.2 | 55.8% |
| ValueRay Target Price | 34.1 | -14.5% |
CNXC Fundamental Data Overview February 01, 2026
P/E Forward = 3.2425
P/S = 0.2367
P/B = 0.8668
P/EG = 0.3603
Revenue TTM = 9.83b USD
EBIT TTM = -891.9m USD
EBITDA TTM = -728.7m USD
Long Term Debt = 4.57b USD (from longTermDebt, last quarter)
Short Term Debt = 65.6m USD (from shortTermDebt, last quarter)
Debt = 4.64b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.31b USD (from netDebt column, last quarter)
Enterprise Value = 6.64b USD (2.33b + Debt 4.64b - CCE 327.3m)
Interest Coverage Ratio = -3.07 (Ebit TTM -891.9m / Interest Expense TTM 290.3m)
EV/FCF = 11.59x (Enterprise Value 6.64b / FCF TTM 572.5m)
FCF Yield = 8.63% (FCF TTM 572.5m / Enterprise Value 6.64b)
FCF Margin = 5.83% (FCF TTM 572.5m / Revenue TTM 9.83b)
Net Margin = -13.02% (Net Income TTM -1.28b / Revenue TTM 9.83b)
Gross Margin = 33.30% ((Revenue TTM 9.83b - Cost of Revenue TTM 6.55b) / Revenue TTM)
Gross Margin QoQ = 27.92% (prev 34.43%)
Tobins Q-Ratio = 0.62 (Enterprise Value 6.64b / Total Assets 10.76b)
Interest Expense / Debt = 1.51% (Interest Expense 69.9m / Debt 4.64b)
Taxrate = 21.0% (US default 21%)
NOPAT = -704.6m (EBIT -891.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.40 (Total Current Assets 3.08b / Total Current Liabilities 2.20b)
Debt / Equity = 1.69 (Debt 4.64b / totalStockholderEquity, last quarter 2.74b)
Debt / EBITDA = -5.92 (negative EBITDA) (Net Debt 4.31b / EBITDA -728.7m)
Debt / FCF = 7.53 (Net Debt 4.31b / FCF TTM 572.5m)
Total Stockholder Equity = 3.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.24% (Net Income -1.28b / Total Assets 10.76b)
RoE = -33.22% (Net Income TTM -1.28b / Total Stockholder Equity 3.85b)
RoCE = -10.59% (EBIT -891.9m / Capital Employed (Equity 3.85b + L.T.Debt 4.57b))
RoIC = -8.13% (negative operating profit) (NOPAT -704.6m / Invested Capital 8.66b)
WACC = 4.03% (E(2.33b)/V(6.96b) * Re(9.70%) + D(4.64b)/V(6.96b) * Rd(1.51%) * (1-Tc(0.21)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 8.01%
[DCF Debug] Terminal Value 88.31% ; FCFF base≈515.0m ; Y1≈626.3m ; Y5≈1.03b
Fair Price DCF = 418.8 (EV 30.11b - Net Debt 4.31b = Equity 25.80b / Shares 61.6m; r=5.90% [WACC]; 5y FCF grow 23.12% → 2.90% )
EPS Correlation: -0.99 | EPS CAGR: 0.92% | SUE: -2.49 | # QB: 0
Revenue Correlation: 91.32 | Revenue CAGR: 14.51% | SUE: 1.41 | # QB: 3
EPS next Quarter (2026-05-31): EPS=2.74 | Chg30d=-0.210 | Revisions Net=-2 | Analysts=3
EPS current Year (2026-11-30): EPS=12.17 | Chg30d=-0.082 | Revisions Net=-1 | Growth EPS=+8.5% | Growth Revenue=+3.4%
EPS next Year (2027-11-30): EPS=13.32 | Chg30d=-0.658 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+2.7%
P/S = 0.2367
P/B = 0.8668
P/EG = 0.3603
Revenue TTM = 9.83b USD
EBIT TTM = -891.9m USD
EBITDA TTM = -728.7m USD
Long Term Debt = 4.57b USD (from longTermDebt, last quarter)
Short Term Debt = 65.6m USD (from shortTermDebt, last quarter)
Debt = 4.64b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.31b USD (from netDebt column, last quarter)
Enterprise Value = 6.64b USD (2.33b + Debt 4.64b - CCE 327.3m)
Interest Coverage Ratio = -3.07 (Ebit TTM -891.9m / Interest Expense TTM 290.3m)
EV/FCF = 11.59x (Enterprise Value 6.64b / FCF TTM 572.5m)
FCF Yield = 8.63% (FCF TTM 572.5m / Enterprise Value 6.64b)
FCF Margin = 5.83% (FCF TTM 572.5m / Revenue TTM 9.83b)
Net Margin = -13.02% (Net Income TTM -1.28b / Revenue TTM 9.83b)
Gross Margin = 33.30% ((Revenue TTM 9.83b - Cost of Revenue TTM 6.55b) / Revenue TTM)
Gross Margin QoQ = 27.92% (prev 34.43%)
Tobins Q-Ratio = 0.62 (Enterprise Value 6.64b / Total Assets 10.76b)
Interest Expense / Debt = 1.51% (Interest Expense 69.9m / Debt 4.64b)
Taxrate = 21.0% (US default 21%)
NOPAT = -704.6m (EBIT -891.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.40 (Total Current Assets 3.08b / Total Current Liabilities 2.20b)
Debt / Equity = 1.69 (Debt 4.64b / totalStockholderEquity, last quarter 2.74b)
Debt / EBITDA = -5.92 (negative EBITDA) (Net Debt 4.31b / EBITDA -728.7m)
Debt / FCF = 7.53 (Net Debt 4.31b / FCF TTM 572.5m)
Total Stockholder Equity = 3.85b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.24% (Net Income -1.28b / Total Assets 10.76b)
RoE = -33.22% (Net Income TTM -1.28b / Total Stockholder Equity 3.85b)
RoCE = -10.59% (EBIT -891.9m / Capital Employed (Equity 3.85b + L.T.Debt 4.57b))
RoIC = -8.13% (negative operating profit) (NOPAT -704.6m / Invested Capital 8.66b)
WACC = 4.03% (E(2.33b)/V(6.96b) * Re(9.70%) + D(4.64b)/V(6.96b) * Rd(1.51%) * (1-Tc(0.21)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 8.01%
[DCF Debug] Terminal Value 88.31% ; FCFF base≈515.0m ; Y1≈626.3m ; Y5≈1.03b
Fair Price DCF = 418.8 (EV 30.11b - Net Debt 4.31b = Equity 25.80b / Shares 61.6m; r=5.90% [WACC]; 5y FCF grow 23.12% → 2.90% )
EPS Correlation: -0.99 | EPS CAGR: 0.92% | SUE: -2.49 | # QB: 0
Revenue Correlation: 91.32 | Revenue CAGR: 14.51% | SUE: 1.41 | # QB: 3
EPS next Quarter (2026-05-31): EPS=2.74 | Chg30d=-0.210 | Revisions Net=-2 | Analysts=3
EPS current Year (2026-11-30): EPS=12.17 | Chg30d=-0.082 | Revisions Net=-1 | Growth EPS=+8.5% | Growth Revenue=+3.4%
EPS next Year (2027-11-30): EPS=13.32 | Chg30d=-0.658 | Revisions Net=-1 | Growth EPS=+9.4% | Growth Revenue=+2.7%